Trial Profile

A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Patients With Familial Adenomatous Polyposis

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 May 2025 According to Biodexa Pharmaceuticals media release, Biodexa Pharmaceuticals collaboration partner Rapamycin Holdings and Emtora Biosciences received additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas to support this study,total grant awarded by CPRIT to support this study is $20 million.
12 May 2025 According to a Biodexa Pharmaceuticals media release, the Phase 3 study is supported by a 17.0 million grant from the Cancer Prevention Research Institute of Texas (CPRIT) and a Company match of $8.5 million
30 Apr 2025 Status changed from planning to not yet recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com